To see the adjunctive use of HD-tACS as a tool to improve cognitive functioning in schizophrenia patients.
Phase 3
- Conditions
- Health Condition 1: F20- Schizophrenia
- Registration Number
- CTRI/2021/11/038189
- Lead Sponsor
- Central institute of psychiatry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
DIAGNOSIS OF SCHIZOPHRENIA USING ICD-10.
SCHIZOPHRENIA ILLNESS DURATION MORE THAN 2 YEAR & ON STABLE DOSE OF ANTIPSYCHOTICS.
MONTREAL COGNITIVE ASSESSMENT TEST SCORE 25 OR MORE.
RIGHT HANDED PEOPLE.
PATIENT GIVING WRITTEN INFORMED CONSENT.
Exclusion Criteria
PRECENCE OF CO-MORBID NEUROLOGICAL DISORDER.
CLINICALLY DIAGNOSED INTELLECTUAL DISABILITY.
PAST HISTORY OF SEIZURE EPISODE.
PAST HISTORY OF SIGNIFICANT HEAD INJURY.
PATIENT RECEIVED ECT IN LAST 6 MONTH.
CALGARY DEPRESSION SCALE FOR SCHIZOPHRENIA SCORE MORE THAN 7.
SIMPSON ANGUS SCALE SCORE MORE THAN 0.65.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary outcome of the study is changes in cognitive function in patients with schizophrenia as assessed by neuropsychological tests at baseline and at the completion of adjunctive online theta frequency tACS after 5 days.Timepoint: Assessed at baseline and at the completion of adjunctive <br/ ><br>HD-tACS after 5 days.
- Secondary Outcome Measures
Name Time Method Secondary outcome is change in schizophrenic symptoms as measured by PANSS at baseline and after completion of adjunctive online theta frequency tACS after 5 days.Timepoint: Assessed at the baseline and at the completion of adjunctive <br/ ><br>HD-tACS after 5 days.